1. ¹Department of Pathology, UH 2G332/0054, University of Michigan Medical School and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109-0054, USA
2. ²Department of Pediatrics, University of Michigan Medical School, University of Michigan, Ann Arbor, MI 48109-0054, USA
3. ³Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI 48109-0054, USA
4. ⁴Department of Pathology, University of Cincinnati Medical School, Cincinnati, OH, USA
5. ⁵Department of Statistics, University of Michigan Medical School, University of Michigan, Ann Arbor, MI 48109-0054, USA
6. ⁶Department of Surgery, University of Michigan Medical School, University of Michigan, Ann Arbor, MI 48109-0054, USA

Correspondence: TJ Giordano, E-mail: Giordano@umich.edu

Received 1 March 2005; Revised 25 April 2005; Accepted 26 April 2005; Published online 27 June 2005.

Abstract

Thyroid cancer poses a significant clinical challenge, and our understanding of its pathogenesis is incomplete. To gain insight into the pathogenesis of papillary thyroid carcinoma, transcriptional profiles of four normal thyroids and 51 papillary carcinomas (PCs) were generated using DNA microarrays. The tumors were genotyped for their common activating mutations: BRAF V600E point mutation, RET/PTC1 and 3 rearrangement and point mutations of KRAS, HRAS and NRAS. Principal component analysis based on the entire expression data set separated the PCs into three groups that were found to reflect tumor morphology and mutational status. By combining expression profiles with mutational status, we defined distinct expression profiles for the BRAF, RET/PTC and RAS mutation groups. Using small numbers of genes, a simple classifier was able to classify correctly the mutational status of all 40 tumors with known mutations. One tumor without a detectable mutation was predicted by the classifier to have a RET/PTC rearrangement and was shown to contain one by fluorescence in situ hybridization analysis. Among the mutation-specific expression signatures were genes whose differential expression was a direct consequence of the mutation, as well as genes involved in a variety of biological processes including immune response and signal transduction. Expression of one mutation-specific differentially expressed gene, TPO, was validated at the protein level using immunohistochemistry and tissue arrays containing an independent set of tumors. The results demonstrate that mutational status is the primary determinant of gene expression variation within these tumors, a finding that may have clinical and diagnostic significance and predicts success for therapies designed to prevent the consequences of these mutations.